Focal Segmental Glomerulosclerosis
📧 Sign up to get email alerts when something new happens for Focal Segmental Glomerulosclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-25Clinical Trial Results: Obinutuzumab in Primary FSGS [Phase 2]
Phase 2 trial results evaluating obinutuzumab for primary focal segmental glomerulosclerosis have been completed and results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: SLIT ABS: Study on Patients With Autoimmune Podocytopathy [NA]
This clinical trial update indicates the SLIT ABS study for autoimmune podocytopathy is currently recruiting, sponsored by Meyer Children's …
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation [Phase 3]
Phase 3 trial evaluating Acthar for focal segmental glomerulosclerosis in patients undergoing renal transplantation has completed with resul…
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis [Phase 2]
Phase 2 study of BI-764198 in people with focal segmental glomerulosclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis [Phase 2]
Phase 2 study evaluating R3R01 in patients with Alport syndrome and focal segmental glomerulosclerosis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-11Clinical Trial Update: Obinutuzumab in Primary FSGS [Phase 2]
A Phase 2 trial evaluating obinutuzumab for primary focal segmental glomerulosclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant [EARLY_Phase 1]
This update reports the completion of an early-phase trial assessing preemptive rituximab to prevent recurrence of focal segmental glomerulo…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment [Phase 1]
This completed Phase 1 study evaluated the pharmacokinetics and safety of Inaxaplin in participants with mild or moderate hepatic impairment…
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease [Phase 2]
A Phase 2 clinical trial evaluating tumor necrosis factor inhibition for focal segmental glomerulosclerosis and treatment-resistant minimal …
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System [NA]
An update on a post-approval clinical study evaluating the LIPOSORBER LA-15 lipoprotein apheresis system for drug-resistant adult and pediat…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) [Phase 3]
A Phase 3 study evaluating sparsentan for primary focal segmental glomerulosclerosis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) [Phase 2]
Phase 2 trial of PF-06730512 in adults with focal segmental glomerulosclerosis (FSGS) was terminated; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome [Phase 2]
Phase 2 study of CCX140-B in subjects with primary FSGS and nephrotic syndrome was terminated. Results have been posted on 2024-02-06.
-
CLINICAL_TRIALS trial_result · 2023-12-05Clinical Trial Update: A Study of CCX140-B in Subjects With FSGS [Phase 2]
Phase 2 trial of CCX140-B in subjects with focal segmental glomerulosclerosis has completed, with results posted in December 2023.
-
CLINICAL_TRIALS trial_result · 2023-07-10Clinical Trial Update: Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis [Phase 2]
Phase 2a trial of VX-147 in adults with APOL1-mediated focal segmental glomerulosclerosis has completed, and results were posted in July 202…
-
CLINICAL_TRIALS trial_result · 2022-07-29Clinical Trial Update: Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan [Phase 2]
Phase 2 clinical trial evaluating safety and effectiveness of propagermanium in patients with focal segmental glomerulosclerosis receiving i…
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX [Phase 2]
Phase 2 trial evaluating bardoxolone methyl in rare chronic kidney diseases has completed, with results posted January 18, 2022. Diseases st…
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients [Phase 2]
Phase 2 trial evaluating Bleselumab for preventing recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients …
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis [Phase 2]
Phase 2 dose-exploration trial evaluating voclosporin for focal segmental glomerulosclerosis was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis [Phase 2]
A Phase 2 randomized, double-blind study evaluating sparsentan (RE-021) for safety and efficacy in focal segmental glomerulosclerosis has co…
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) [Phase 2]
Phase 2 pilot study evaluating abatacept for safety and efficacy in adults and children 6+ with nephrotic syndrome due to FSGS or minimal ch…
-
CLINICAL_TRIALS trial_result · 2020-08-03Clinical Trial Update: FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS) [Phase 2]
Phase 2 clinical trial update for CXA-10 in primary focal segmental glomerulosclerosis has been completed.
-
CLINICAL_TRIALS trial_result · 2020-02-10Clinical Trial Update: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS [Phase 2]
Phase 2 pilot trial assessing rituximab for treatment-resistant focal segmental glomerulosclerosis has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2018-09-20Clinical Trial Update: Rituximab to Prevent Recurrence of Proteinuria [Phase 3]
Phase 3 trial update on rituximab to prevent recurrence of proteinuria in FSGS; the study was terminated with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-08-27Clinical Trial Update: Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome [Phase 3]
A Phase 3 trial compares rituximab to continued corticosteroid treatment in idiopathic nephrotic syndrome, including minimal change disease …